2. Anti-infection Metabolic Enzyme/Protease
  3. Bacterial Parasite Endogenous Metabolite
  4. Paromomycin

Paromomycin (Aminosidine) is an orally active broad-spectrum aminoglycoside aminocyclitol. Paromomycin is produced by Streptomyces riomosus var. Paromomycinus. Paromomycin binding induces local conformational changes in the 16S rRNA A-site. Paromomycin exhibits inhibitory activity against C. parvum. Paromomycin can be used in research related to leishmaniasis, amoebiasis and cryptosporidiosis.

For research use only. We do not sell to patients.

Paromomycin

Paromomycin Chemical Structure

CAS No. : 7542-37-2

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Paromomycin:

Other Forms of Paromomycin:

Paromomycin Related Antibodies

Top Publications Citing Use of Products

View All Parasite Isoform Specific Products:

View All Isoforms
Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms
Human Endogenous Metabolite Microbial Metabolite

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Paromomycin (Aminosidine) is an orally active broad-spectrum aminoglycoside aminocyclitol. Paromomycin is produced by Streptomyces riomosus var. Paromomycinus. Paromomycin binding induces local conformational changes in the 16S rRNA A-site. Paromomycin exhibits inhibitory activity against C. parvum. Paromomycin can be used in research related to leishmaniasis, amoebiasis and cryptosporidiosis[1][2][3].

IC50 & Target[1]

Microbial Metabolite

 

Leishmania

 

Amebae

 

Cellular Effect
Cell Line Type Value Description References
HCT-8 IC50
711 nM
Compound: Paromomycin
Antimicrobial activity against Cryptosporidium parvum infected in human HCT-8 cells after 48 hrs by ELISA
Antimicrobial activity against Cryptosporidium parvum infected in human HCT-8 cells after 48 hrs by ELISA
[PMID: 18591280]
J774.A1 CC50
53.33 μg/mL
Compound: Paromomycin
Cytotoxicity against mouse J774A1 cells by MTT assay
Cytotoxicity against mouse J774A1 cells by MTT assay
[PMID: 21295472]
Peritoneal macrophage cell IC50
> 100 μM
Compound: paromomycin
Cytotoxicity against mouse Peritoneal macrophages cells after 72 hrs by MTS assay
Cytotoxicity against mouse Peritoneal macrophages cells after 72 hrs by MTS assay
[PMID: 22989363]
RAW264.7 IC50
> 100 μM
Compound: paromomycin
Cytotoxicity against mouse RAW264.7 cells after 72 hrs by MTS assay
Cytotoxicity against mouse RAW264.7 cells after 72 hrs by MTS assay
[PMID: 22989363]
Vero CC50
53.3 μM
Compound: Paromomycin
Cytotoxicity against african green monkey vero cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against african green monkey vero cells assessed as cell viability after 72 hrs by MTT assay
[PMID: 23673014]
In Vitro

Paromomycin inhibits Cryptosporidium parvum infection of the differentiated human enterocyte cell line HT29.74[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Paromomycin Related Antibodies
In Vivo

Paromomycin (1-2 g/kg/day; p.o.; 10 consecutive days) reduces C. parvum infection in immunosuppressed adult C57BL/6N mice, as demonstrated by significant reductions in fecal oocyst shedding (P < 0.01), parasite colonization (P < 0.05), and villus atrophy (P < 0.05) in the ilea and terminal ilea[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6N (female, 6 weeks old, 14-16 g, immunosuppressed with dexamethasone phosphate, infected with Cryptosporidium parvum)[3]
Dosage: 0.25 g/kg/day; 0.5 g/kg/day; 1 g/kg/day; 2 g/kg/day
Administration: p.o.; once daily; 10 consecutive days
Result: Significantly reduced fecal oocyst shedding (P < 0.01) at 1 g/kg/day and 2 g/kg/day, with no rebound after initial reduction.
Significantly lowered parasite colonization in ilea (0.02 ± 0.02 C.
parvum/epithelial cell at 1 g/kg/day; 0 C.
parvum/epithelial cell at 2 g/kg/day) and terminal ilea (0.15 ± 0.08 C.
parvum/epithelial cell at 1 g/kg/day; 0.03 ± 0.03 C.
parvum/epithelial cell at 2 g/kg/day) compared to placebo controls (P < 0.05).
Increased villus-to-crypt (V/C) ratios in ilea (1.99 ± 0.08 at 1 g/kg/day; 1.98 ± 0.02 at 2 g/kg/day) and terminal ilea (1.81 ± 0.11 at 1 g/kg/day; 1.91 ± 0.07 at 2 g/kg/day) compared to placebo controls (P < 0.05), indicating reduced villus atrophy.
Reduced oocyst shedding within 24 hours at 0.25 g/kg/day and 0.5 g/kg/day, but rebound occurred starting on day 14 post-infection with shedding exceeding pretreatment levels.
Showed no significant therapeutic benefit for parasite colonization or villus atrophy relative to placebo controls at 0.25 g/kg/day and 0.5 g/kg/day.
Molecular Weight

615.63

Formula

C23H45N5O14
CAS No.
SMILES

O[C@H]([C@@H]([C@H](O1)CO)O[C@H]2O[C@H]([C@H]([C@@H]([C@H]2N)O)O)CN)[C@@H]1O[C@H]([C@H]([C@@H](C[C@@H]3N)N)O)[C@@H]3O[C@H]4O[C@@H]([C@H]([C@@H]([C@H]4N)O)O)CO
Structure Classification
Initial Source

Streptomyces sp
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Paromomycin Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Paromomycin7542-37-2AminosidineBacterialParasiteEndogenous MetaboliteEntamoeba histolyticaCryptosporidium parvumLeishmania species30S ribosomal subunitHT29.7416S ribosomal RNAC57BL/6N miceDientamoeba fragilisGiardia lamblialeishmaniasisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Paromomycin
Cat. No.:
HY-B0956A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.